The brain endocannabinoid system in the regulation of energy balance.
The role played by the endocannabinoid system in the regulation of energy balance is currently generating a great amount of interest among several groups of investigators. This interest in large part comes from the urgent need to develop anti-obesity and anti-cachexia drugs around target systems (such as the endocannabinoid system), which appears to be genuinely involved in energy balance regulation. When activated, the endocannabinoid system favors energy deposition through increasing energy intake and reducing energy expenditure. This system is activated in obesity and following food deprivation, which further supports its authentic function in energy balance regulation. The cannabinoid receptor type 1 (CB1), one of the two identified cannabinoid receptors, is expressed in energy-balance brain structures that are also able to readily produce or inactivate N-arachidonoyl ethanolamine (anandamide) and 2-arachidonoylglycerol (2AG), the most abundantly formed and released endocannabinoids. The brain action of endocannabinoid system on energy balance seems crucial and needs to be delineated in the context of the homeostatic and hedonic controls of food intake and energy expenditure. These controls require the coordinated interaction of the hypothalamus, brainstem and limbic system and it appears imperative to unravel those interplays. It is also critical to investigate the metabolic endocannabinoid system while considering the panoply of functions that the endocannabinoid system fulfills in the brain and other tissues. This article aims at reviewing the potential mechanisms whereby the brain endocannabinoid system influences the regulation energy balance.
Richard
Denis
D
Laval Hospital Research Center, Québec, Canada, G1V 4G5. denis.richard@crhl.ulaval.ca
Guesdon
Benjamin
B
Timofeeva
Elena
E
D000818:Animals; D001921:Brain / Q000378:metabolism*; D063385:Cannabinoid Receptor Modulators / Q000502:physiology*; D063388:Endocannabinoids; D004734:Energy Metabolism / Q000502:physiology*; D007028:Hypothalamic Hormones / Q000502:physiology; D047908:Intracellular Signaling Peptides and Proteins / Q000502:physiology; D008543:Melanins / Q000502:physiology; D009479:Neuropeptides / Q000502:physiology; D000068797:Orexins; D010907:Pituitary Hormones / Q000502:physiology; D012333:RNA, Messenger / Q000378:metabolism; D043884:Receptor, Cannabinoid, CB1 / Q000502:physiology; D012201:Reward
D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D007028:Hypothalamic Hormones; D047908:Intracellular Signaling Peptides and Proteins; D008543:Melanins; D009479:Neuropeptides; D000068797:Orexins; D010907:Pituitary Hormones; D012333:RNA, Messenger; D043884:Receptor, Cannabinoid, CB1; C019463:melanin-concentrating hormone